Stocks Overview

LAST PRICE
165.5200
TODAY'S CHANGE (%)
Trending Up0.8800 (0.5345%)

Bid / Lots
165.3500/ 10
Ask / Lots
165.6500/ 1
Open / Previous Close
164.7400 / 164.6400
Day Range
Low 163.8200
High 165.7500
52 Week Range
Low 143.1300
High 168.8500
Volume
3,693,548
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TSX Comp
TSX Venture
DJIA
S&P 500
NASDAQ

Price Comparison Graph. See accessible table below

1 Day Comparison Chart Accessibility Table. Thursday's close: 164.64
Time	Volume	JNJ
09:32 ET	65395	164.63
09:34 ET	14779	164.6
09:36 ET	11798	164.115
09:38 ET	15709	164.03
09:39 ET	14342	163.9
09:41 ET	8618	164.13
09:43 ET	11510	164.53
09:45 ET	9511	164.65
09:48 ET	9546	164.8
09:50 ET	15829	164.74
09:52 ET	10803	164.84
09:54 ET	6330	164.54
09:56 ET	7029	164.36
09:57 ET	4041	164.39
09:59 ET	7095	164.75
10:01 ET	17379	164.99
10:03 ET	13660	164.87
10:06 ET	4189	164.6
10:08 ET	10026	164.3
10:10 ET	6254	164.265
10:12 ET	9482	164.4601
10:14 ET	13226	164.7
10:15 ET	10887	164.58
10:17 ET	13204	164.69
10:19 ET	3659	164.7
10:21 ET	3845	164.67
10:24 ET	4650	164.785
10:26 ET	9508	165.03
10:28 ET	4389	164.99
10:30 ET	4615	164.905
10:32 ET	7964	164.97
10:33 ET	2221	164.9
10:35 ET	3396	164.98
10:37 ET	8586	165.03
10:39 ET	5491	165.08
10:42 ET	13483	165.09
10:44 ET	2957	165.14
10:46 ET	9411	165.13
10:48 ET	5055	165.095
10:50 ET	2407	165.08
10:51 ET	3491	164.97
10:53 ET	3930	164.785
10:55 ET	7741	164.7468
10:57 ET	6163	164.84
11:00 ET	11065	164.74
11:02 ET	6087	164.785
11:04 ET	5091	164.74
11:06 ET	3657	164.77
11:08 ET	6197	164.86
11:09 ET	2353	164.73
11:11 ET	3907	164.7917
11:13 ET	1636	164.685
11:15 ET	9587	164.64
11:18 ET	5955	164.66
11:20 ET	2706	164.74
11:22 ET	2958	164.77
11:24 ET	4279	164.76
11:26 ET	5115	164.88
11:27 ET	10859	164.69
11:29 ET	6096	164.81
11:31 ET	6263	164.85
11:33 ET	6940	164.91
11:36 ET	6431	164.94
11:38 ET	4571	164.955
11:40 ET	3906	164.9
11:42 ET	5511	164.84
11:44 ET	4137	164.955
11:45 ET	10302	165.04
11:47 ET	3763	165.08
11:49 ET	6581	165.095
11:51 ET	6589	165.04
11:54 ET	6124	165.18
11:56 ET	3745	165.12
11:58 ET	3400	165.105
12:00 ET	4754	165.15
12:02 ET	4876	165.185
12:03 ET	7667	165.16
12:05 ET	6358	165.14
12:07 ET	9769	165.29
12:09 ET	6212	165.27
12:12 ET	6984	165.32
12:14 ET	18044	165.22
12:16 ET	4028	165.28
12:18 ET	4615	165.28
12:20 ET	4329	165.25
12:21 ET	3979	165.082
12:23 ET	4731	165.1187
12:25 ET	3897	165.04
12:27 ET	4422	165.085
12:30 ET	7146	165.15
12:32 ET	10453	165.1399
12:34 ET	3266	165.16
12:36 ET	3856	165.29
12:38 ET	5512	165.28
12:39 ET	6799	165.25
12:41 ET	5216	165.32
12:43 ET	7273	165.35
12:45 ET	3075	165.33
12:48 ET	2276	165.4
12:50 ET	8403	165.33
12:52 ET	4711	165.32
12:54 ET	5118	165.4313
12:56 ET	13570	165.46
12:57 ET	10027	165.485
12:59 ET	13029	165.43
01:01 ET	2932	165.39
01:03 ET	6932	165.45
01:06 ET	4810	165.53
01:08 ET	6263	165.56
01:10 ET	2463	165.53
01:12 ET	3079	165.58
01:14 ET	6699	165.63
01:15 ET	3427	165.66
01:17 ET	5276	165.57
01:19 ET	4037	165.61
01:21 ET	2757	165.5552
01:24 ET	7533	165.53
01:26 ET	8332	165.54
01:28 ET	6141	165.57
01:30 ET	4645	165.57
01:32 ET	9311	165.5
01:33 ET	8005	165.53
01:35 ET	2425	165.5601
01:37 ET	5530	165.56
01:39 ET	7272	165.645
01:42 ET	20418	165.64
01:44 ET	4634	165.6
01:46 ET	6609	165.59
01:48 ET	2141	165.606
01:50 ET	4159	165.6
01:51 ET	5907	165.48
01:53 ET	5233	165.48
01:55 ET	2932	165.4829
01:57 ET	7831	165.45
02:00 ET	3852	165.43
02:02 ET	4000	165.185
02:04 ET	4794	165.26
02:06 ET	2555	165.23
02:08 ET	5623	165.29
02:09 ET	11950	165.5295
02:11 ET	22210	165.51
02:13 ET	8842	165.41
02:15 ET	48712	165.499
02:18 ET	11332	165.47
02:20 ET	7761	165.56
02:22 ET	5775	165.54
02:24 ET	12366	165.5
02:26 ET	9430	165.43
02:27 ET	12177	165.4299
02:29 ET	3778	165.37
02:31 ET	11337	165.35
02:33 ET	7850	165.47
02:36 ET	11350	165.477
02:38 ET	7227	165.49
02:40 ET	8034	165.48
02:42 ET	7775	165.44
02:44 ET	4894	165.47
02:45 ET	8681	165.42
02:47 ET	4317	165.45
02:49 ET	2843	165.45
02:51 ET	4351	165.42
02:54 ET	5657	165.43
02:56 ET	5531	165.4236
02:58 ET	9641	165.46
03:00 ET	5869	165.44
03:02 ET	9706	165.3801
03:03 ET	12749	165.41
03:05 ET	2825	165.43
03:07 ET	16859	165.47
03:09 ET	7643	165.52
03:12 ET	5330	165.46
03:14 ET	5757	165.43
03:16 ET	4925	165.47
03:18 ET	7201	165.565
03:20 ET	9439	165.6
03:21 ET	8993	165.545
03:23 ET	9105	165.52
03:25 ET	7704	165.54
03:27 ET	9018	165.59
03:30 ET	9830	165.55
03:32 ET	7217	165.53
03:34 ET	13103	165.555
03:36 ET	10006	165.51
03:38 ET	8945	165.59
03:39 ET	16817	165.55
03:41 ET	35802	165.56
03:43 ET	12825	165.63
03:45 ET	16606	165.65
03:48 ET	18119	165.7088
03:50 ET	26836	165.58
03:52 ET	19069	165.545
03:54 ET	15830	165.66
03:56 ET	16555	165.58
03:57 ET	29781	165.45
03:59 ET	646380	165.52

Data delayed at least 15 minutes.

Today
- New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer, from 17 hours ago by Dow Jones
  17 hours ago by Dow Jones
Yesterday
- RYBREVANT(R) (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer, from 9:45AM ET on Saturday Sep 14, 2024 by Dow Jones
  9:45AM ET on Saturday Sep 14, 2024 by Dow Jones
- RYBREVANT(R) (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer, from 3:10AM ET on Saturday Sep 14, 2024 by Dow Jones
  3:10AM ET on Saturday Sep 14, 2024 by Dow Jones
Sep 11, 2024
- TREMFYA(R) (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel disease, from 6:22PM ET on Wednesday Sep 11, 2024 by Dow Jones
  6:22PM ET on Wednesday Sep 11, 2024 by Dow Jones
Sep 10, 2024
- Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT(R) (amivantamab-vmjw), from 5:15PM ET on Tuesday Sep 10, 2024 by Dow Jones
  5:15PM ET on Tuesday Sep 10, 2024 by Dow Jones

1 New Today

Industry Peers Overview Table
Company sortable	Market Cap sortable	P/E Ratio (TTM) sortable	EPS Growth (5yr) sortable
United StatesJNJ Johnson & Johnson	398.4B	24.8x	-1.47%
United StatesRHHBY Roche Holding AG	255.1B	20.1x	+3.28%
United StatesABBV AbbVie Inc	343.0B	65.0x	-6.05%
United StatesMRK Merck & Co Inc	293.7B	21.5x	-43.23%
United StatesNVS Novartis AG	253.2B	23.6x	-5.59%
United StatesAZN AstraZeneca PLC	242.6B	37.9x	+17.52%
As of 2024-09-15

Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. It operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, interventional solutions, cardiovascular intervention, and vision fields. The MedTech segment also offers a commercially available intravascular lithotripsy (IVL) platform for coronary artery disease (CAD) and peripheral artery disease (PAD).

Contact Information

Headquarters: One Johnson & Johnson PlazaNEW BRUNSWICK, NJ, United States 08933
Phone: 732-524-2455
Fax: 732-214-0332

Executives

Chairman of the Board, Chief Executive Officer: Joaquin Duato
Chief Financial Officer, Executive Vice President: Joseph Wolk
Chief Human Resource Officer, Executive Vice President: Peter Fasolo
Executive Vice President, Chief Technology Officer and Risk Officer: Kathryn Wengel
Executive Vice President, Chief Information Officer: James Swanson

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Skip section

INK Company InsiderDetailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®.

Fundamentals Table
Market Cap	$398.4B
Revenue (TTM)	$86.6B
Shares Outstanding	2.4B
Dividend Yield	3.00%
Annual Dividend Rate	4.9600 USD
Ex-Dividend Date	08-27-24
Pay Date	09-10-24
Beta	0.52
EPS	$6.66
Book Value	$28.57
P/E Ratio	24.8x
Price/Sales (TTM)	4.6
Price/Cash Flow (TTM)	17.1x
Operating Margin	22.53%

*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Johnson & Johnson
NYSE:JNJUnited States

Search Criteria

Charts

Recent News

Today

New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer, from 17 hours ago by Dow Jones

Yesterday

RYBREVANT(R) (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer, from 9:45AM ET on Saturday Sep 14, 2024 by Dow Jones

RYBREVANT(R) (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer, from 3:10AM ET on Saturday Sep 14, 2024 by Dow Jones

Sep 11, 2024

TREMFYA(R) (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel disease, from 6:22PM ET on Wednesday Sep 11, 2024 by Dow Jones

Sep 10, 2024

Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT(R) (amivantamab-vmjw), from 5:15PM ET on Tuesday Sep 10, 2024 by Dow Jones

Pharmaceuticals - Diversified Industry Peers

Company Information

Contact Information

Executives

Ratings

Reports

Fundamentals

Calendar